Oregon Public Employees Retirement Fund Takes $482,000 Position in Amneal Pharmaceuticals, Inc. $AMRX

Oregon Public Employees Retirement Fund purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 1st quarter, according to its most recent disclosure with the SEC. The fund purchased 38,800 shares of the company’s stock, valued at approximately $482,000.

A number of other institutional investors have also added to or reduced their stakes in AMRX. Rubric Capital Management LP increased its position in Amneal Pharmaceuticals by 5.3% during the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock worth $123,473,000 after purchasing an additional 624,609 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals by 3.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock valued at $70,681,000 after buying an additional 177,906 shares in the last quarter. Morgan Stanley grew its stake in shares of Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares during the last quarter. Nantahala Capital Management LLC grew its stake in shares of Amneal Pharmaceuticals by 14.7% during the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock worth $35,333,000 after buying an additional 558,877 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Amneal Pharmaceuticals by 3.4% during the fourth quarter. State Street Corp now owns 4,110,410 shares of the company’s stock worth $51,791,000 after buying an additional 136,662 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on AMRX shares. Barclays raised their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. UBS Group started coverage on Amneal Pharmaceuticals in a research note on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Weiss Ratings lowered shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, May 26th. Finally, Wall Street Zen upgraded shares of Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday. Five equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $15.80.

Insider Buying and Selling

In other Amneal Pharmaceuticals news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $12.94, for a total transaction of $450,557.86. Following the completion of the sale, the director owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 17.30% of the stock is owned by insiders.

Amneal Pharmaceuticals Stock Down 2.9%

NASDAQ AMRX opened at $16.69 on Wednesday. The company has a market capitalization of $5.32 billion, a price-to-earnings ratio of 43.92 and a beta of 1.26. Amneal Pharmaceuticals, Inc. has a twelve month low of $7.66 and a twelve month high of $17.86. The stock has a fifty day simple moving average of $14.80 and a 200 day simple moving average of $13.80.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. Research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current fiscal year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.